BACKGROUND: New safe and effective treatments for Chagas disease (CD) are urgently needed. Current chemotherapy options for CD have significant limitations, including failure to uniformly achieve parasitological cure or prevent the chronic phase of CD, and safety and tolerability concerns. Fexinidazole, a 2-subsituted 5-nitroimidazole drug candidate rediscovered following extensive compound mining by the Drugs for Neglected Diseases initiative and currently in Phase I clinical study for the treatment of human African trypanosomiasis, was evaluated in experimental models of acute and chronic CD caused by different strains of Trypanosoma cruzi. METHODS AND FINDINGS: We investigated the in vivo activity of fexinidazole against T. cruzi, using mice as hosts. The T. cruzi strains used in the study were previously characterized in murine models as susceptible (CL strain), partially resistant (Y strain), and resistant (Colombian and VL-10 strains) to the drugs currently in clinical use, benznidazole and nifurtimox. Our results demonstrated that fexinidazole was effective in suppressing parasitemia and preventing death in infected animals for all strains tested. In addition, assessment of definitive parasite clearance (cure) through parasitological, PCR, and serological methods showed cure rates of 80.0% against CL and Y strains, 88.9% against VL-10 strain, and 77.8% against Colombian strain among animals treated during acute phase, and 70% (VL-10 strain) in those treated in chronic phase. Benznidazole had a similar effect against susceptible and partially resistant T. cruzi strains. Fexinidazole treatment was also shown to reduce myocarditis in all animals infected with VL-10 or Colombian resistant T. cruzi strains, although parasite eradication was not achieved in all treated animals at the tested doses. CONCLUSIONS: Fexinidazole is an effective oral treatment of acute and chronic experimental CD caused by benznidazole-susceptible, partially resistant, and resistant T. cruzi. These findings illustrate the potential of fexinidazole as a drug candidate for the treatment of human CD.
BACKGROUND: New safe and effective treatments for Chagas disease (CD) are urgently needed. Current chemotherapy options for CD have significant limitations, including failure to uniformly achieve parasitological cure or prevent the chronic phase of CD, and safety and tolerability concerns. Fexinidazole, a 2-subsituted 5-nitroimidazole drug candidate rediscovered following extensive compound mining by the Drugs for Neglected Diseases initiative and currently in Phase I clinical study for the treatment of human African trypanosomiasis, was evaluated in experimental models of acute and chronic CD caused by different strains of Trypanosoma cruzi. METHODS AND FINDINGS: We investigated the in vivo activity of fexinidazole against T. cruzi, using mice as hosts. The T. cruzi strains used in the study were previously characterized in murine models as susceptible (CL strain), partially resistant (Y strain), and resistant (Colombian and VL-10 strains) to the drugs currently in clinical use, benznidazole and nifurtimox. Our results demonstrated that fexinidazole was effective in suppressing parasitemia and preventing death in infected animals for all strains tested. In addition, assessment of definitive parasite clearance (cure) through parasitological, PCR, and serological methods showed cure rates of 80.0% against CL and Y strains, 88.9% against VL-10 strain, and 77.8% against Colombian strain among animals treated during acute phase, and 70% (VL-10 strain) in those treated in chronic phase. Benznidazole had a similar effect against susceptible and partially resistant T. cruzi strains. Fexinidazole treatment was also shown to reduce myocarditis in all animals infected with VL-10 or Colombian resistant T. cruzi strains, although parasite eradication was not achieved in all treated animals at the tested doses. CONCLUSIONS:Fexinidazole is an effective oral treatment of acute and chronic experimental CD caused by benznidazole-susceptible, partially resistant, and resistant T. cruzi. These findings illustrate the potential of fexinidazole as a drug candidate for the treatment of humanCD.
Authors: Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse Journal: Antimicrob Agents Chemother Date: 2008-12-15 Impact factor: 5.191
Authors: Antoaneta Y Sokolova; Susan Wyllie; Stephen Patterson; Sandra L Oza; Kevin D Read; Alan H Fairlamb Journal: Antimicrob Agents Chemother Date: 2010-05-03 Impact factor: 5.191
Authors: Simone Garcia; Carolina O Ramos; Juliana F V Senra; Fabio Vilas-Boas; Maurício M Rodrigues; Antonio C Campos-de-Carvalho; Ricardo Ribeiro-Dos-Santos; Milena B P Soares Journal: Antimicrob Agents Chemother Date: 2005-04 Impact factor: 5.191
Authors: Margoth Moreno; Daniella A D'ávila; Marcelo N Silva; Lúcia Mc Galvão; Andrea M Macedo; Egler Chiari; Eliane D Gontijo; Bianca Zingales Journal: Mem Inst Oswaldo Cruz Date: 2010-11 Impact factor: 2.743
Authors: Lívia de Figueiredo Diniz; Ivo Santana Caldas; Paulo Marcos da Matta Guedes; Geovam Crepalde; Marta de Lana; Cláudia Martins Carneiro; André Talvani; Julio Alberto Urbina; Maria Terezinha Bahia Journal: Antimicrob Agents Chemother Date: 2010-04-19 Impact factor: 5.191
Authors: Sérgio Caldas; Fabiane M Santos; Marta de Lana; Lívia F Diniz; George L L Machado-Coelho; Vanja M Veloso; Maria T Bahia Journal: Exp Parasitol Date: 2007-09-07 Impact factor: 2.011
Authors: Els Torreele; Bernadette Bourdin Trunz; David Tweats; Marcel Kaiser; Reto Brun; Guy Mazué; Michael A Bray; Bernard Pécoul Journal: PLoS Negl Trop Dis Date: 2010-12-21
Authors: Maria T Bahia; Alvaro F S Nascimento; Ana Lia Mazzeti; Luiz F Marques; Karolina R Gonçalves; Ludmilla W R Mota; Lívia de F Diniz; Ivo S Caldas; André Talvani; David M Shackleford; Maria Koltun; Jessica Saunders; Karen L White; Ivan Scandale; Susan A Charman; Eric Chatelain Journal: Antimicrob Agents Chemother Date: 2014-05-19 Impact factor: 5.191
Authors: Juan Carlos Villar; Juan Guillermo Perez; Olga Lucia Cortes; Adelina Riarte; Micah Pepper; Jose Antonio Marin-Neto; Gordon H Guyatt Journal: Cochrane Database Syst Rev Date: 2014-05-27
Authors: Sivaraman Dandapani; Andrew R Germain; Ivan Jewett; Sebastian le Quement; Jean-Charles Marie; Giovanni Muncipinto; Jeremy R Duvall; Leigh C Carmody; Jose R Perez; Juan C Engel; Jiri Gut; Danielle Kellar; Jair Lage Siqueira-Neto; James H McKerrow; Marcel Kaiser; Ana Rodriguez; Michelle A Palmer; Michael Foley; Stuart L Schreiber; Benito Munoz Journal: ACS Med Chem Lett Date: 2013-12-29 Impact factor: 4.345
Authors: Rômulo Dias Novaes; Eliziária C Santos; Marli C Cupertino; Daniel S S Bastos; Jerusa M Oliveira; Thaís V Carvalho; Mariana M Neves; Leandro L Oliveira; André Talvani Journal: Parasitol Res Date: 2015-04-28 Impact factor: 2.289
Authors: Yukiko Miyamoto; Jaroslaw Kalisiak; Keith Korthals; Tineke Lauwaet; Dae Young Cheung; Ricardo Lozano; Eduardo R Cobo; Peter Upcroft; Jacqueline A Upcroft; Douglas E Berg; Frances D Gillin; Valery V Fokin; K Barry Sharpless; Lars Eckmann Journal: Proc Natl Acad Sci U S A Date: 2013-10-07 Impact factor: 11.205